Solventum reported Q4 FY2025 net sales of USD 2.0 billion, down 3.7% on a reported basis, with organic sales up 3.5%. GAAP diluted EPS was USD 0.36 and adjusted diluted EPS was USD 1.57. Q4 operating cash flow was USD 96 million and free cash flow was USD 33 million. For FY2025, Solventum posted net sales of USD 8.3 billion, up 0.9%, with net income of USD 1.6 billion (up 224.8%) and GAAP diluted EPS of USD 8.88 (up 221.7%); adjusted diluted EPS was USD 6.11, down 8.8%. FY2025 operating cash flow was USD 369 million and free cash flow was no free cash flow, versus USD 805 million a year earlier. In Q4, organic sales growth was driven by Infection Prevention and Surgical Solutions within MedSurg as well as Dental Solutions. The company said debt paydown following the September 2025 sale of its Purification and Filtration business was the primary driver of the increase in adjusted EPS, while adjusted results also reflected operating expense savings and tariff headwinds. Solventum introduced FY2026 guidance for organic sales growth of 2.0% to 3.0%, adjusted EPS of USD 6.40 to USD 6.60, and free cash flow of about USD 200 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602261605PR_NEWS_USPR_____CG96456) on February 26, 2026, and is solely responsible for the information contained therein.